1. Home
  2. ODFL vs INSM Comparison

ODFL vs INSM Comparison

Compare ODFL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Old Dominion Freight Line Inc.

ODFL

Old Dominion Freight Line Inc.

HOLD

Current Price

$207.11

Market Cap

34.7B

Sector

Industrials

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$152.48

Market Cap

33.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ODFL
INSM
Founded
1934
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.7B
33.5B
IPO Year
1991
2000

Fundamental Metrics

Financial Performance
Metric
ODFL
INSM
Price
$207.11
$152.48
Analyst Decision
Buy
Strong Buy
Analyst Count
20
24
Target Price
$166.84
$192.27
AVG Volume (30 Days)
2.1M
2.7M
Earning Date
02-04-2026
02-19-2026
Dividend Yield
0.59%
N/A
EPS Growth
N/A
N/A
EPS
4.97
N/A
Revenue
$5,574,922,000.00
$447,022,000.00
Revenue This Year
N/A
$53.83
Revenue Next Year
$2.41
$138.44
P/E Ratio
$38.20
N/A
Revenue Growth
N/A
30.34
52 Week Low
$126.01
$60.40
52 Week High
$209.61
$212.75

Technical Indicators

Market Signals
Indicator
ODFL
INSM
Relative Strength Index (RSI) 81.63 36.22
Support Level $169.99 $150.80
Resistance Level $175.79 $158.98
Average True Range (ATR) 6.24 6.52
MACD 1.98 0.15
Stochastic Oscillator 99.11 10.08

Price Performance

Historical Comparison
ODFL
INSM

About ODFL Old Dominion Freight Line Inc.

Old Dominion Freight Line is the second-largest less-than-truckload carrier in the United States (following FedEx Freight), with more than 250 service centers and 11,000-plus tractors. It is one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns are head and shoulders above its peers. Strategic initiatives revolve around boosting network density through market share gains and maintaining industry-leading service (including ultralow cargo claims) via steadfast infrastructure investment.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: